Evidence map›Paper›PMID 37244879›Full record

ReviewWorld journal of urology2023

A 10-year renaissance of en bloc resection of bladder tumors (ERBT): Are we approaching the peak or is it back to the trough?

Dmitry Enikeev, Andrey Morozov, Anastasia Shpikina, Harun Fajkovic, Jack Baniel, Thomas R W Herrmann

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Translational andrology and urology · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 6 countries.

Dmitry EnikeevDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. dvenikeev@gmail.com.ORCID http://orcid.org/0000-0001-7169-2209
Andrey MorozovInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Anastasia ShpikinaInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Harun FajkovicDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Jack BanielDivision of Urology, Rabin Medical Center, Petach Tikva, Israel.
Thomas R W HerrmannDepartment of Urology, Spital Thurgau AG (STGAG), Frauenfeld, Switzerland.
Sechenov University · RUKarl Landsteiner Society · ATStellenbosch University · ZATel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe number of studies suggesting that en bloc resection of bladder tumor (ERBT) is superior to transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer (NMIBC) management is growing. The aim of this review is to discuss the features of these procedures and to determine the prospects of en bloc in NMIBC management. MATERIALS AND

methodsWe conducted a literature search using two databases (Medline and Scopus) and included any research which reported ERBT outcomes.

resultsThe lasers with minimal tissue penetration depth are becoming the main tool for ERBT. Unfortunately, most of the systematic reviews continue to be characterized by high heterogeneity. However, recent studies indicate that ERBT may have the edge when it comes to the detrusor muscle rate and the quality of the histological specimen. ERBT may favor in terms of in-field relapse, but its rate in the studies varies greatly. As for out-field relapse-free survival, the data are still lacking. The strongest evidence supports that ERBT is superior to TURBT in complications rate (bladder perforation). ERBT is feasible irrespective to tumor size and location.

conclusionsERBT has gained in momentum with the increasingly widespread use of this kind of laser surgery. The introduction of novel sources (TFL and Thulium:YAG pulsed laser) will definitely affect how the field develops and will result in further improvements in safety and precision. The latest trials make us more certain in our belief that ERBT will be beneficial in terms of histological specimen quality, relapse rate and complications rate.

Indexed as

Urinary Bladder NeoplasmsCystectomyHumansLasersRecurrenceUrologic Surgical ProceduresBladder cancerEn blocNMIBCResection

Identifiers

PMID37244879
OpenAlexW4378549315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.